Physician
Endocrinology
Dr. Priscilla A. Hollander, MD
|
|
Give Review
Priscilla Hollander practices Endocrinology. She went to Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care She received 2 awards: "Regional Top Doctor" and "Super Doctor". Priscilla Hollander is a published physician as well. She has 62 publications published. The latest was: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. She accepts all Medicare patients.
Publications
- Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 Diabetes on ...
- Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With T...
- Weight maintenance and additional weight loss With liraglutide after low-calorie-diet-induced weight loss: The Scale Maintenance randomized study.
- Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 Diabetes (BEGIN: Flex T1): a 26-week randomized, treat...
- Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 Diabetes (T-emerge 7 study).
- Controversies in preDiabetes: do we have a diagnosis?
- Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance.
- Type 2 Diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
- Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 Diabetes.
- Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 Diabetes: a 3-year randomized contr...
- Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 Diabetes.
- Body weight changes associated With insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled ...
- Evolution of a pulmonary insulin delivery system (Exubera) for patients with Diabetes.
- Effectiveness of Diabetes resource nurse case management and physician profiling in a fee-for-service setting: a cluster randomized trial.
- Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 Diabetes: results of a 6-month, randomized, compara...
- Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 Diabetes: a 1-year randomized controlled trial.
- Orlistat: A Viewpoint by Priscilla A. Hollander.
- Impact of an EHR-based Diabetes management form on quality and outcomes of Diabetes care in primary care practices.
- A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy.
- Evaluation of the control of glucagon secretion by the parasympathetic nervous system in man.
- A practical guide to using insulin.
- The case for tight control in Diabetes.
- The need to address sexual dysfunction in Diabetes.
- Diabetes in pregnancy. No longer a barrier to successful outcome.
- Gestational Diabetes. Ensuring optimal outcome for mother and child.
- Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma.
- Orlistat in the treatment of Obesity.
- Insulin, pancreatic polypeptide, and glucagon antibodies in insulin-dependent Diabetes mellitus.
- Type II Diabetes. More than 'just a touch' of Diabetes.
- Premixed insulins. How do they compare With other insulin preparations?
- Acarbose in the treatment of type I Diabetes.
- Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
- Low-dose rosiglitazone in patients with insulin-requiring type 2 Diabetes.
- A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 Diabetes.
- Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 Diabetes and inadequate control on thiazolidinedione alone.
- Clinical outcomes in patients with type 2 Diabetes managed by a Diabetes resource nurse in a primary care practice.
- A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in Obesity.
- Adjust to target in type 2 Diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.
- Quality of care of Medicare patients with Diabetes in a metropolitan fee-for-service primary care integrated delivery system.
- Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 Diabetes: a randomised controlled study.
- Current trends in treating type 2 Diabetes.
- Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 Diabetes: A 1-year randomized controlled trial.
- Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 Diabetes after failure of two oral drugs: efficacy, safety, and cost analysis.
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 Diabetes approaching glycaemic targets.
- A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir With insulin glargine in a basal-bolus regimen wi...
- Efficacy and safety of insulin detemir once daily in combination With sitagliptin and metformin: the TRANSITION randomized controlled trial.
- Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 Diabetes mellitus.
- Intensified insulin regimens. Should they be used in all patients with type I Diabetes?
- New oral agents for type II Diabetes. Taking a more aggressive approach to therapy.
- Effect of orlistat in overweight and obese patients with type 2 Diabetes treated with metformin.
- Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 Diabetes.
- Role of orlistat in the treatment of obese patients with type 2 Diabetes. A 1-year randomized double-blind study.
- Effect of pramlintide on weight in overweight and obese insulin-treated type 2 Diabetes patients.
- Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
- A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese Type 2 d...
- SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy With rimonabant, the first selective CB1 receptor antagonist...
- Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
- Basal insulin or premix analogue therapy in type 2 Diabetes patients.
- Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 Diabetes: A 3-year randomized contr...
- Effect of rimonabant on glycemic control in insulin-treated type 2 Diabetes: the ARPEGGIO trial.
- Insulin detemir for the treatment of obese patients with type 2 Diabetes.
Schools
Harvard Medical School
Dallas Co Hp Parkland Mem
Conditions Treated
- Abnormal Thyroid
- Adrenal Incidentaloma
- Calcium Metabolism Disorders
- Diabetes Type 1
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
Harvard Medical School
Hospital
-
Baylor University Medical Center
Drug Facts
| NPI NUMBER | 1417988098 | |
| NPPES Provider LastName | HOLLANDER | |
| NPPES Provider FirstName | PRISCILLA | |
| NPPES Provider ZIPCode | 752461800 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 4477.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417988098 |
| Last Name Of The Provider | HOLLANDER |
| First Name Of The Provider | PRISCILLA |
| View All |
Similar Doctors
|
|
Dr. Joseph L. Milburn, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Rajiv Dattatreya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Feferman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Qing Jia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul Lyde, MD
This Doctor is OpenDoctor Recommended.
|